John D. Halpern 13D and 13G filings for BROOKLYN IMMUNO THERAPEUTICS L:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-01-31 07:05 am Purchase |
2023-12-31 | 13G | Eterna Therapeutics Inc. ERNA |
John D. Halpern | 550,894 9.990% |
98,611 (+21.80%) |
Filing |
| 2023-01-31 4:05 pm Purchase |
2023-01-31 | 13G | Eterna Therapeutics Inc. ERNA |
John D. Halpern | 452,283 8.800% |
1,117 (+0.25%) |
Filing |
| 2022-12-05 5:20 pm Sale |
2022-12-02 | 13G | Eterna Therapeutics Inc. ERNA |
John D. Halpern | 451,166 8.800% |
-4,296,079 (-90.50%) |
Filing |
| 2021-05-24 1:03 pm Purchase |
2021-03-25 | 13G | Eterna Therapeutics Inc. ERNA |
John D. Halpern | 237,362 11.400% |
237,362 (New Position) |
Filing |